Recent Updates
Recently added Catalysts
BWAY Positive Sentiment

Deep TMS: A comprehensive summary of adverse events from five multicenter trials

Wednesday, July 26, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article summarizes the adverse event profile of Deep TMS treatments using H1, H4, and H7 Coils from five multicenter randomized controlled trials involving 884 patients. It highlights the frequency and types of adverse events, noting that most were transient and resolved within days. This analysis represents a significant contribution to understanding the safety of Deep TMS.
Price reaction · baseline $1.115 (2023-07-26T13:30:00.000Z) · hit during market hours · 1 other BWAY headline(s) in the window, move may be shared
day 0 close · peak
+9%
day 1
+5.6%
day 3
+9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Comprehensive overview of adverse events from multiple trials.
  • Focus on transient adverse events that resolved quickly.
  • Large sample size of 884 patients enhances reliability.

Full Press Release Details

This paper provides a concise overview of the adverse event profile of the H1, H4, and H7 Coils as studied in five (5) large, multicenter, randomized controlled trials (RCTs) consisting of 884 patients. The analysis is the most comprehensive review of both the frequency and types of adverse events associated with Deep TMS treatment.
Results are summarized in the table below. M ost of the adverse events reported were transient and resolved within days.

Frequently Asked Questions

What is the focus of the study on Deep TMS?

The study focuses on the adverse event profile of Deep TMS treatments using H1, H4, and H7 Coils.

How many patients were involved in the trials?

The trials involved a total of 884 patients across five multicenter studies.

What types of adverse events were reported?

The analysis summarized both the frequency and types of adverse events associated with Deep TMS.

How long did the adverse events last?

Most adverse events reported were transient and resolved within days.

ShareAdd on Google
Tags: BWAY Viatris Investor Conferences Healthcare Deep TMS adverse events H1 H4 H7 Coils multicenter trials
Last updated: Jul 26, 2023

Biotech snapshot

Lead asset
SIR2501Phase 2
Chemotherapy-induced Peripheral Neuropathy →